Neurology Alert – August 1, 2004
August 1, 2004
View Issues
-
Parkinson’s Disease — A New Mutation Leads to Potential New Insights Into Disease Pathogenesis
Converging evidence implicates both protein aggregation as well as oxidative damage in mitochondrial dysfunction in Parkinsons disease pathogenesis. It is likely that these factors may interact. -
What’s the Cause of Normal Aging? — Part 2
These findings are amongst the most direct data to date that oxidative damage plays a critical role in normal human aging. -
US Map of Deaths from Stroke in Children Similar to that Seen for Adults
This is the latest of several important publications by Dr. Fullerton and her colleagues, at The University of California at San Francisco, describing details of the epidemiology of pediatric stroke during the last 2 decades of the 20th century. -
New Concern About Old Drugs
These papers and the accompanying editorial by Rascol bring attention to a known but under-recognized complication of ergot derivatives. -
Stroke Prevention Strategies Are Successful
The good news from the Oxford Vascular Study is that community-wide risk factor modifications and preventive treatment are worth the effort, and that further reductions in stroke incidence are possible with more widespread stroke prevention programs. -
Transient Global Amnesia: Unlocking an Ischemic Etiology
Treatment of TGA patients with antiplatelet treatment is likely warranted, particularly if there are underlying vascular risk factors. -
Lidocaine Patch for Diabetic Neuropathy
Evidence suggests that Erythropoietin acts by stimulating neuroprotective pathways, including the protein kinase B cascade and the transcription factor nuclear factor-kB pathway, to activate antiapoptotic and antioxidant factors. -
Leflunomide Peripheral Neuropathy
Leflunomides immunomodulatory activity derives from its action as a competitive inhibitor of the rate-limiting enzyme necessary for pyrimidine synthesis. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: Importance of Publishing Negative Clinical Studies
Sources of funding for pharmaceutical research has come under scrutiny in the last decade as academic and government sources of funding have become increasingly scarce and the pharmaceutical industry has become the main source of research dollars. But the issue of objectivity has been raised, and some have even suggested that negative studies, that is studies that show a drug in an unfavorable light, may never be published. The American Medical Association has recently tackled this issue.